ACCELERATED DISTRIBUTION DEMONSTRATION SYSTEM

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR:9012120041 DOC.DATE: 90/12/07 NOTARIZED: NO DOCKET #
FACIL:50-250 Turkey Point Plant, Unit 3, Florida Power and Light C 05000250
50-251 Turkey Point Plant, Unit 4, Florida Power and Light C 05000251
50-335 St. Lucie Plant, Unit 1, Florida Power & Light Co. 05000335
50-389 St. Lucie Plant, Unit 2, Florida Power & Light Co. 05000389
AUTH.NAME AUTHOR AFFILIATION
BOHLKE,W.H. Florida Power & Light Co.
RECIP.NAME RECIPIENT AFFILIATION
Document Control Branch (Document Control Desk)

SUBJECT: Forwards Roche Biochemical Labs rept re unsatisfactory performance testing incident,per 10CFR26,App A.2.8(e)(4).

DISTRIBUTION CODE: A001D COPIES RECEIVED:LTR 1 ENCL 1 SIZE: 3
TITLE: OR Submittal: General Distribution

NOTES:

	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL
	PD2-2 LA	1	1	PD2-2 PD	1	1
	EDISON,G	2	2	NORRIS,J	2	2
INTERNAL:	ACRS	6	6	NRR/DET/ECMB 9H	1	1
	NRR/DET/ESGB	1	1	NRR/DOEA/OTSB11	1	1
	NRR/DST 8E2	1	1	NRR/DST/SELB 8D	1	1
	NRR/DST/SICB 7E	1	1	NRR/DST/SRXB 8E	1	1
	NUDOCS-ABSTRACT	1	1	OC/LFMB	1	0
	OGC/HDS2	1	0	REG FILE 01	1	1
	RES/DSIR/EIB	1	1			
EXTERNAL:	NRC PDR	1	1	NSIC	1	1

NRR/DRIS/RSGB 1 1

NOTE TO ALL "RIDS" RECIPIENTS:

PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM P1-37 (EXT. 20079) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR ~~26~~ 27 ENCL ~~24~~ 25

RIDS/ADDS

RIDS/ADDS

RIDS/ADDS

FPL

P.O. Box 14000, Juno Beach, FL 33408-0420

DECEMBER 07 1990

L-90-429
10 CFR 26

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, D.C. 20555

Gentlemen:

Re: Turkey Point Units 3 and 4
Docket Nos. 50-250 and 50-251
St Lucie Units 1 and 2
Docket Nos. 50-335 and 50-389
10 CFR 26 Unsatisfactory Performance
Testing Incident Report

Pursuant to 10 CFR 26 Appendix A.2.8(e)(4), Florida Power & Light Company (FPL) is submitting to the NRC the enclosed report of an unsatisfactory performance testing incident.

In accordance with the requirements of 10 CFR 26, Appendix A, Section 2.8(e), FPL submitted blind performance test specimens to FPL's contract Department of Health and Human Services (DHHS) certified laboratory, Roche Biomedical Laboratories. The enclosed report details the investigative analysis of unsatisfactory blind specimen results, the identification of causes, and the corrective actions taken by the laboratory to prevent recurrence.

Please contact us if additional information is required.

Very truly yours,

W. H. Bohlke
Vice President
Nuclear Engineering and Licensing

WHB/DMB/lef

Enclosure

cc: Stewart D. Ebneter, Regional Administrator, Region II, USNRC
Senior Resident Inspector, USNRC, Turkey Point Plant
Senior Resident Inspector, USNRC, St. Lucie Plant

A001 1/1 Add: NRR/DRIS/RSGB 4 Encl 1 1

Roche Biomedical Laboratories
a subsidiary of Hoffmann-La Roche Inc.

Roche Biomedical Laboratories, Inc.
P.O. Box 13973
Research Triangle Park, North Carolina 27709

Telephone: 919 361-7700

November 19, 1990

Mr. Art Cummings
Fitness for Duty Supervisor
Florida Power and Light
700 Universe Boulevard
P.O. Box 14000
Juno Beach, FL 33408-0420

Dear Mr. Cummings:

The investigation concerning the blind quality control sample is described in the attached report.

Should you require additional information please call me at (919) 361-7712. Thank you for your cooperation.

Sincerely yours,

Paula S. Childs, Ph.D., D-ABFT
Co-Director, Toxicology

Blind Quality Control Sample #243-000-5043

PROBLEM:

The report for blind quality control sample #243-000-5043 (RBL# 245-700-0930) was transmitted as "Negative". The blind quality control specimen was positive for amphetamine and methamphetamine.

ANALYSIS:

The blind quality control sample identified above was collected on August 31, 1990, and received at the Roche Biomedical Laboratory in Research Triangle Park, NC, on September 2, 1990. The Accessioning Clerk assigned the laboratory number 245-700-0930 to the chain of custody request and blind quality control sample bottle.

The blind quality control sample was screened on September 2, 1990 and found to be positive for amphetamine(s). The re-screen (performed on September 4, 1990) was also positive for amphetamines. The blind quality control sample was scheduled for GC/MS confirmation of amphetamines (amphetamine and/or methamphetamine).

The blind quality control sample was extracted in preparation for GC/MS confirmation of amphetamines on September 4, 1990. The analysis was completed, indicating 696 ng/mL amphetamine and 3207 ng/mL methamphetamine. However, the ion ratios for the internal standard failed to meet the acceptance criteria. The specimen was scheduled for re-extraction. This re-extraction resulted in a similar result, with the internal standard failing to meet acceptance criteria. According to the standard operating procedure, this specimen failed to meet criteria for reporting as positive. Thus, the result was reported as negative.

CORRECTIVE ACTION:

The corrective action which has been initiated has included the introduction of another confirmation test for amphetamines. The procedure which has been in use since October 24, 1990 utilizes the heptafluorobutyric acid anhydride (HFBA) derivative of amphetamine and methamphetamine. This procedure has replaced the use of the 4-carbethoxyhexafluorobutyryl (4-CB) derivative which was previously in use.

Respectfully submitted,

Paula S. Childs, Ph.D., D-ABFT
Co-Director, Forensic Toxicology